Generali Investments Towarzystwo Funduszy Inwestycyjnych Buys Shares of 600 Zoetis Inc. (NYSE:ZTS)

Generali Investments Towarzystwo Funduszy Inwestycyjnych bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 600 shares of the company’s stock, valued at approximately $98,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its stake in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 140 shares in the last quarter. Darwin Wealth Management LLC purchased a new position in Zoetis during the 3rd quarter valued at about $31,000. First Personal Financial Services bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP bought a new stake in shares of Zoetis in the 3rd quarter valued at approximately $33,000. Finally, Dunhill Financial LLC grew its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after buying an additional 75 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on ZTS. Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Leerink Partners began coverage on Zoetis in a research note on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Two analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Stock Down 0.0 %

ZTS opened at $164.95 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The firm has a market cap of $73.86 billion, a P/E ratio of 30.16, a price-to-earnings-growth ratio of 2.78 and a beta of 0.90. The business has a 50 day moving average price of $166.25 and a 200 day moving average price of $177.49. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion during the quarter, compared to analyst estimates of $2.30 billion. Research analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.